- In January 2023, Cipla Limited has introduced Cippoint, an advanced point-of-care testing device that provides a broad spectrum of tests, including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. This device, which has received CE IVD approval, meets the standards set by the European In-Vitro Diagnostic Device Directive, ensuring its reliability and accuracy in testing
- In September 2021, F. Hoffmann-La Roche AG has announced a definitive agreement to acquire all outstanding shares of the TIB Molbiol Group. This acquisition will strengthen Roche's extensive portfolio of molecular diagnostics by adding a diverse array of assays, including those for detecting SARS-CoV-2 variants and other infectious diseases
